ParcelBio
Elevated mRNA for transformative medicines.
ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.
- Website
- parcelbio.com
- City
- San Francisco
- Country
- United States
- YC batch
- Winter 2024
- Team
- 6 people
- Stage
- Early stage
- AI-native
- No
More Health & bio in San Francisco
Innovaccer$1.3bn
Indian digital healthcare company.
Thatch$1bn
Health benefits. Valued at $1bn (September 2026).
Chan Zuckerberg BiohubLab
Nonprofit research network building virtual cell models.
AthelasHiring
Extensible, Integrated Technology that Simplifies Health Systems
ClipboardHiring
Every shift, Covered.
Benchling
Unlocking the power of biotech with modern software for modern science
Claim this profile
Free and instant: prove you run parcelbio.com and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to ParcelBio across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with ParcelBio's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
